Need Tally
for Clients?

Contact Us! Here

  Tally Auditor

License (Renewal)
  Tally Gold

License Renewal

  Tally Silver

License Renewal
  Tally Silver

New Licence
  Tally Gold

New Licence
 
Open DEMAT Account with in 24 Hrs and start investing now!
Service Tax »
Open DEMAT Account in 24 hrs
 Filing ITR? Maximize Your Tax Savings With These 7 Allowance Benefits
 Extension of time limit for compliance to be made for claiming any exemption under Section 54 to 54GB of the Income-tax Act, 1961 ('Act') in view of the then-Covid-19 pandemic
 Missed Income Tax Return filing due date for AY 2022-23? Here s one more chance
 What are the tax saving investments other than section 80C for senior citizens?
 Gross Direct Tax Collections for FY 2022-23 register growth of 25.90%
 Your guide to tax saving with insurance-cum-investment products
 Govt likely to meet non-tax revenue target for FY23
 What is the tax liability for a senior citizen?
 Notification No.121/2022 CENTRAL BOARD OF DIRECT TAXES
 How tax on rental income is calculated: Step-by-step guide
 Moonlighting for additional income? Know the income tax rules

Keep clinical trial services out of service tax ambit
September, 04th 2014

The Association of Biotechnology Led Enterprises (ABLE) has requested the government to consider keeping clinical trial services out of the ambit of service tax.

As per the Union budget, these services, which were previously exempt, would now attract service tax of 12.36 per cent. The move, industry players say, would increase the cost of drug development in the country and lead to a corresponding increase in the price of the tested drugs.

"Drug development in India is already facing challenges on several fronts following which the number of global and local clinical trials has come down substantially.

The decreased number of trials will impact availability of drugs in the medium-to-long term and will increase dependence of Indian patients on imported drugs. We have urged for keeping these services out of the service tax for another five years," ABLE said in a statement here.

On July 28, the CDSCO (the Drug Organisation in India) had invited suggestions on its notification for improving its clinical trials management through application of IT. Though a laudable step, ABLE and Association of Contract Research Organisations ( ACRO) India have cautioned the DCGI (Drug Controller of India) to preserve confidentiality of the patients.

The industry body has also requested to retain the existing CTRI website for clear visibility of clinical trials in the country.

ABLE President Dr P M Murali said, "India's pharma and biotech industry has the potential to generate combined revenues of more than $ 100 billion by 2025 from approximately $ 25 billion as of today. To realise this quantum of growth, the right policy framework needs to be put in place. The sector must be provided with incentives through a number of tax-friendly measures to make it globally competitive."

Home | About Us | Terms and Conditions | Contact Us
Copyright 2023 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting